|
|
Volumn 330, Issue 6009, 2010, Pages 1298-1299
|
|
A powerful and perplexing new HIV prevention tool
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
DEOXYCYTIDINE;
DRUG DERIVATIVE;
ORGANOPHOSPHORUS COMPOUND;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
COST EFFECTIVENESS ANALYSIS;
EXPOSURE;
GEOGRAPHIC DISTRIBUTION;
HIGH RISK POPULATION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
NOTE;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
TREATMENT OUTCOME;
ANTIVIRAL RESISTANCE;
DISEASE TRANSMISSION;
DRUG COMBINATION;
DRUG COST;
DRUG EFFECT;
FEMALE;
HOMOSEXUALITY;
HUMAN IMMUNODEFICIENCY VIRUS;
MALE;
PATIENT COMPLIANCE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
TRANSSEXUALISM;
ANTI-HIV AGENTS;
DEOXYCYTIDINE;
DRUG COMBINATIONS;
DRUG COSTS;
DRUG RESISTANCE, VIRAL;
FEMALE;
HIV;
HIV INFECTIONS;
HOMOSEXUALITY, MALE;
HUMANS;
MALE;
MEDICATION ADHERENCE;
ORGANOPHOSPHORUS COMPOUNDS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
TRANSSEXUALISM;
|
|
EID: 78649703085
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.330.6009.1298 Document Type: Note |
|
Times cited : (8)
|
|
References (0)
|
